If everything goes as planned, this week will be the busiest for initial public offerings since 2000.
VIDEO ON MSN MONEY
This high-yielding oil and gas royalty trust is still a buy after its recent run-up.
By Paul Tracy, Top 10 Stocks
As a royalty trust, SandRidge Mississippian Trust (SDT) owns a stake in dozens of wells run by its parent company SandRidge Energy (SD).
When you see all-too-rare sell calls, you'd better duck and cover.
By Jeff Reeves
Wall Street is a rigged game. And if you're an individual investor with just a few thousand dollars at play, the quicker you learn this, the better off you'll be.
Right now, we're in the middle of earnings season, one of the biggest pieces of Wall Street theater, and lots of folks will be crowing about "beating expectations." But consider that most stocks in the S&P 500 index have beaten the Street every year since the third quarter of 1998. Particularly galling was that in Q3 of 2009, right after the market bottomed, nearly 80% of companies in the S&P topped forecasts.
The drugmaker is creating a buzz because of its recently approved blood cancer treatment and its potential as a buyout candidate..
Even as a relatively young drugmaker, Incyte (INCY) is already creating buzz because of its recently approved blood cancer treatment -- and its potential as a takeover target. The stock has been in an uptrend of late, climbing to $16.87 a share on Jan. 13, 2011, from $11.80 on Nov. 25. Some analysts see the stock driving up to as high as $25 over the next 12 months. The stock hit a 52-week high of $21 last year.
Much of the stock's recent strength has been due to the Food and Drug Administration's approval on Nov. 16, 2011, of Incyte's chief product, Jakafi, a drug for the treatment of high-risk myelofibrosis, a life-threatening type of blood cancer. Incyte is partnering with Novartis (NVS) for the marketing of the drug outside the U.S. starting later this year.
Every high-flying market is bound to find patches of rough air, and the charts show a potential decline is in store. However, several plays should defy these trends.
By Tom Aspray, MoneyShow.com
Even disappointing retail sales numbers and a pickup in unemployment claims couldn't stop the market from closing higher last Thursday.
However, market internals indicated that the market was struggling to move higher. Each day it seemed a bit weaker, until the sellers stepped in on Friday -- the potential of an S&P downgrade of France’s debt rating was the good reason to sell they were waiting for.
Data released Thursday may be a worrying sign for those monitoring macro trends, but it would be foolish for investors to view all retail stocks through the same prism.
December may have been a less-than-jolly month for retail sales, but that doesn’t mean that investors should demand discount valuations from all retail stocks in the same way that they insist on bargains at the mall.
Yes, the retail sales figures released Thursday disappointed economists and investors, especially those hoping for another "pop" like the ones from September and October (up 0.7% and 0.5%, respectively.) Alas: Despite the annual holiday shopping frenzy, overall retail sales edged up a mere 0.1% over November levels (or 0.2%, leaving out sales of automobiles), the slowest rate reported since May, as economists and analysts were quick to point out. That compares to economists’ forecasts of a 0.3% advance.
The world's biggest payment network benefits mightily from the rise of a global cashless economy.
By Nicholas Vardy, Alpha Investor
A business with steady and rich cash-flow that benefits from an expanding global sector, Visa (V) is one of my favorite long-term ideas.
The final act of the eurozone debt crisis will force the United States down a painful path.
On Friday the 13th, the eurozone's existential nightmare plunged to new depths: Credit analysts at Standard & Poor's who cut America's AAA rating in August made good on their threats and cut France's AAA rating by one notch. They also handed two notch downgrades to Italy and Spain, according to widespread media reports.
This was done in response to a disappointing European Union summit back on Dec. 9 where, instead of addressing the structural issues at the heart of the crisis there -- namely, inadequate banking regulation and lack of true fiscal union -- or measures that could stem the crisis, the focus was on stricter budget discipline and austerity measures. That's the same mistake we made in 1937. And that same mistake was why the Great Depression lasted so long.
The team at S&P wasn't impressed and took action as Europe plunges headlong into a new recession. This, combined with the collapsing Greek bailout, has markets reeling and Wall Street analysts cutting their economic growth estimates. It couldn't come at a worse time.
Shares of the company have fallen amid concerns about the Chevy Volt. But those worries were overblown.
Declines in defaults and delinquencies and the rise of mobile payments offset losses from Dodd-Frank fee caps.
In this article we look at the top three events for the credit card industry in 2011.
With substantial gold and zinc resources, numerous joint ventures and future royalty streams, this stock looks like a bargain.
By Adrian Day, The Global Analyst
Virginia Mines (VGMNF) is arguably one of the most undervalued companies in the gold sector, with low risk but also significant upside.
Shares tanked when CEO Glen Senk announced his departure, but he's part of the problem.
By Jonathan Berr
The abrupt departure of Urban Outfitters' (URBN) CEO Glen Senk sent shares of the Philadelphia retailer reeling. Investors wondered if the ultra-cool parent of its namesake stores, Anthropologie and Free People would be able to recapture its lost mojo. While the stock recovered some of its lost ground, that's a question with no easy answer.
Urban Outfitters is a mess because in the words of Senk, the company has "a fashion issue." That's corporate-speak for the public thinks our clothes are ugly.
They handily outperformed in 2011, but recent technical action suggests the Dow could be more vulnerable than the now-lagging S&P 500.
By Tom Aspray, MoneyShow.com
The stock market is getting ready for next week's heavy schedule of earnings reports. Many Dow components are expected to report next week, including International Business Machines (IBM), Microsoft (MSFT), and Intel (INTC), which are all scheduled for Thursday, Jan. 19.
The Dow Industrials clearly outperformed the S&P 500 in 2011, but so far in 2012, the Spyder Trust (SPY), which tracks the S&P 500, has done about 1% better than the SPDR Diamonds Trust (DIA), which follows the Dow Industrials. But do the market internals and other technical factors favor one index over the other as we enter 2012?
A special variant made in Texas halts production after the parent company sues the bottler.
The soda, produced at the tiny Dublin Dr Pepper Bottling plant in Dublin, Texas, has been a cult favorite for years. Fans loved that it was still made from cane sugar and not high-fructose corn syrup. Locals saw the soda as one of the last economic strongholds in a struggling town with a population of just 3,800.
The bottler even added the word "Dublin" to the labels of its Dr Pepper and sold the soda on its website. In retrospect, that may have been its undoing.
This maker of marine power transmission systems has solid earnings, new products, order backlogs and looks like a bargain.
By Dennis Slothower, Stealth Stocks
If you are looking for a solid growth company currently trading at a discount, then I strongly recommend Twin Disc (TWIN).
Orexigen, once the leading candidate to reach market, expects two more years of safety testing.
A year ago, diet pill maker Orexigen Therapeutics (OREX) was riding high. It looked like the company was about to win a three-way race to sell the first new diet pill in the U.S. in more than a decade.
Orexigen's closest rivals, Vivus (VVUS) and Arena Pharmaceuticals (ARNA), were already knocked out (at least temporarily) as the Food and Drug Administration had rejected applications for their weight-loss pills. Orexigen had the backing of a panel of experts advising the FDA. It looked like the company had defied the odds and was rounding the corner to approval. In rejecting the rival diet pills, the U.S. agency stated strong concerns about the safety of the products.
MORE ON MSN MONEY
Copyright © 2014 Microsoft. All rights reserved.
Ahead of Twitter's second-quarter earnings release, analysts are largely bullish, and investors are watching several metrics closely, especially user growth.
Top Stocks provides analysis about the most noteworthy stocks in the market each day, combining some of the best content from around the MSN Money site and the rest of the Web.
Contributors include professional investors and journalists affiliated with MSN Money.
Follow us on Twitter @topstocksmsn.
[BRIEFING.COM] At midday, the Dow Jones Industrial Average (+0.2%), Nasdaq (+0.3%), and S&P 500 (+0.1%) hold slim gains, while the Russell 2000 (+0.6%) outperforms.
Like yesterday, the overnight session was free of any broad developments, which allowed the focus to turn toward the next batch of earnings in the U.S. In general, most of the reports received since yesterday's closing bell have surpassed expectations, but there were a few noteworthy disappointments too.
Despite ... More
More Market News
|There’s a problem getting this information right now. Please try again later.|